Warmblood fragile foal syndrome

From WikiMD's WELLNESSPEDIA

Warmblood Fragile Foal Syndrome (WFFS) is a genetic disorder that affects warmblood horses. It is characterized by extremely fragile skin that tears easily, joint laxity, and other serious symptoms. The syndrome is caused by a mutation in the PLOD1 gene, which is responsible for the production of an enzyme involved in the formation of collagen, a protein that provides strength and structure to the skin, ligaments, and blood vessels.

Symptoms[edit]

The symptoms of Warmblood Fragile Foal Syndrome are usually apparent at birth. They include:

  • Extremely fragile skin that tears or ulcerates easily
  • Joint laxity, particularly in the fetlocks
  • Hyperextension of the joints
  • Hematomas and bruising
  • Difficulty standing or walking
  • In severe cases, affected foals may be stillborn or euthanized shortly after birth due to the severity of their symptoms.

Causes[edit]

Warmblood Fragile Foal Syndrome is caused by a mutation in the PLOD1 gene. This gene is responsible for the production of an enzyme called lysyl hydroxylase, which is involved in the formation of collagen. When this gene is mutated, the resulting enzyme is unable to function properly, leading to the production of weak, fragile collagen. This in turn leads to the symptoms seen in WFFS.

Diagnosis[edit]

Diagnosis of Warmblood Fragile Foal Syndrome is typically made based on the presence of characteristic symptoms. Genetic testing can also be performed to confirm the diagnosis. This involves taking a blood sample from the foal and testing it for the presence of the PLOD1 mutation.

Treatment[edit]

There is currently no cure for Warmblood Fragile Foal Syndrome. Treatment is supportive and aimed at managing symptoms. This may include wound care for skin tears and ulcers, and pain management for joint issues. In severe cases, euthanasia may be considered to prevent suffering.

Prevention[edit]

As WFFS is a genetic disorder, prevention involves careful breeding practices. Horses known to carry the PLOD1 mutation should not be bred together, as there is a 25% chance that their offspring will inherit the disorder.

See also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.